Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics

Cardiff Oncology, Inc. (CRDF): $3.78

0.57 (+17.76%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add CRDF to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#314 of 328

in industry

CRDF Price/Volume Stats

Current price $3.78 52-week high $6.42
Prev. close $3.20 52-week low $0.94
Day low $3.06 Volume 1,015,200
Day high $3.79 Avg. volume 930,560
50-day MA $2.63 Dividend yield N/A
200-day MA $3.00 Market Cap 175.96M

CRDF Stock Price Chart Interactive Chart >


Cardiff Oncology, Inc. (CRDF) Company Bio


Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


CRDF Latest News Stream


Event/Time News Detail
Loading, please wait...

CRDF Latest Social Stream


Loading social stream, please wait...

View Full CRDF Social Stream

CRDF Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!